Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

1.

Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.

Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.

Transpl Infect Dis. 2013 Apr;15(2):187-94. doi: 10.1111/tid.12037. Epub 2012 Dec 20.

PMID:
23279695
[PubMed - indexed for MEDLINE]
2.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

PMID:
11704785
[PubMed - indexed for MEDLINE]
Free Article
3.

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA.

Blood. 2012 Feb 2;119(5):1117-22. doi: 10.1182/blood-2011-07-370031. Epub 2011 Dec 6.

PMID:
22147893
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.

Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.

Bone Marrow Transplant. 2007 Sep;40(6):557-62. Epub 2007 Jun 25. Erratum in: Bone Marrow Transplant. 2007 Sep;40(6):607.

PMID:
17589534
[PubMed - indexed for MEDLINE]
5.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M.

Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9.

PMID:
21828140
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment.

Cowan AJ, Seldin DC, Skinner M, Quillen K, Doros G, Tan J, O'Hara C, Finn KT, Sanchorawala V.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1935-8. doi: 10.1016/j.bbmt.2012.07.016. Epub 2012 Jul 27.

PMID:
22842332
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.

Br J Haematol. 2007 Oct;139(2):224-33.

PMID:
17897298
[PubMed - indexed for MEDLINE]
8.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
[PubMed - indexed for MEDLINE]
9.

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Ann Hematol. 2010 Jun;89(6):579-84. doi: 10.1007/s00277-009-0874-8. Epub 2009 Dec 10.

PMID:
20012043
[PubMed - indexed for MEDLINE]
10.

Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.

Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz MA.

Blood. 2005 Nov 15;106(10):3353-7. Epub 2005 Jul 21.

PMID:
16037390
[PubMed - indexed for MEDLINE]
Free Article
11.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC.

Blood. 2007 Nov 15;110(10):3561-3. Epub 2007 Aug 2.

PMID:
17673601
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.

N Engl J Med. 2007 Sep 13;357(11):1083-93.

PMID:
17855669
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

[Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis].

Ogura M, Sekine R, Nishiyama S, Abe Y, Iizuka H, Kusaka S, Nakagawa Y, Suzuki K.

Rinsho Ketsueki. 2012 Jul;53(7):710-5. Japanese.

PMID:
22975774
[PubMed - indexed for MEDLINE]
15.

Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.

Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.

Kidney Int. 2003 May;63(5):1868-73.

PMID:
12675865
[PubMed - indexed for MEDLINE]
16.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
[PubMed - indexed for MEDLINE]
17.

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M.

Bone Marrow Transplant. 2004 Feb;33(4):381-8.

PMID:
14676787
[PubMed - indexed for MEDLINE]
18.

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.

Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B.

Bone Marrow Transplant. 2013 Nov;48(12):1537-42. doi: 10.1038/bmt.2013.98. Epub 2013 Jul 15.

PMID:
23852321
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.

Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V.

Blood. 2006 Dec 1;108(12):3945-7. Epub 2006 Aug 22.

PMID:
16926284
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.

Mejhert M, Hast R, Sandstedt B, Janczewska I.

BMJ Case Rep. 2011 Aug 17;2011. pii: bcr0320114007. doi: 10.1136/bcr.03.2011.4007.

PMID:
22688930
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk